MX2017004691A - Bloqueo de cd73. - Google Patents
Bloqueo de cd73.Info
- Publication number
- MX2017004691A MX2017004691A MX2017004691A MX2017004691A MX2017004691A MX 2017004691 A MX2017004691 A MX 2017004691A MX 2017004691 A MX2017004691 A MX 2017004691A MX 2017004691 A MX2017004691 A MX 2017004691A MX 2017004691 A MX2017004691 A MX 2017004691A
- Authority
- MX
- Mexico
- Prior art keywords
- blockade
- cells
- nucleotidase
- ecto
- cancers
- Prior art date
Links
- 102100022464 5'-nucleotidase Human genes 0.000 abstract 2
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 abstract 2
- 102000004008 5'-Nucleotidase Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta invención se relaciona con anticuerpos que unen un epítope presente en CD73 expresado en la superficie de células, que incluyen células tumorales, y que inhiben la actividad enzimática (ecto-5´ nucleotidasa) de la enzima CD73. Tales agentes se pueden utilizar para el tratamiento de enfermedades tal como cánceres.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462062323P | 2014-10-10 | 2014-10-10 | |
US201562118549P | 2015-02-20 | 2015-02-20 | |
US201562133597P | 2015-03-16 | 2015-03-16 | |
US201562188881P | 2015-07-06 | 2015-07-06 | |
PCT/EP2015/073370 WO2016055609A1 (en) | 2014-10-10 | 2015-10-09 | Cd73 blockade |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017004691A true MX2017004691A (es) | 2017-10-02 |
Family
ID=54291300
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017004691A MX2017004691A (es) | 2014-10-10 | 2015-10-09 | Bloqueo de cd73. |
Country Status (16)
Country | Link |
---|---|
US (2) | US10766966B2 (es) |
EP (2) | EP3204417B1 (es) |
JP (2) | JP7037359B2 (es) |
KR (1) | KR102536786B1 (es) |
CN (1) | CN106852149B (es) |
AU (2) | AU2015329982B2 (es) |
BR (1) | BR112017006464A2 (es) |
CA (1) | CA2957813A1 (es) |
DK (1) | DK3204417T3 (es) |
ES (1) | ES2821964T3 (es) |
IL (1) | IL250579B2 (es) |
MX (1) | MX2017004691A (es) |
PT (1) | PT3204417T (es) |
RU (1) | RU2746804C2 (es) |
SG (1) | SG11201701341UA (es) |
WO (1) | WO2016055609A1 (es) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112017006464A2 (pt) | 2014-10-10 | 2018-01-30 | Innate Pharma | bloqueio de cd73 |
JP6755866B2 (ja) | 2014-11-10 | 2020-09-16 | メディミューン リミテッド | Cd73特異的結合分子及びその使用 |
PT3221346T (pt) | 2014-11-21 | 2020-10-23 | Bristol Myers Squibb Co | Anticorpos compreendendo regiões constantes de cadeia pesada modificadas |
MX2017006624A (es) | 2014-11-21 | 2017-08-21 | Bristol Myers Squibb Co | Anticuerpos contra cd73 y sus usos. |
WO2017064043A1 (en) | 2015-10-12 | 2017-04-20 | Innate Pharma | Cd73 blocking agents |
WO2017118613A1 (en) * | 2016-01-08 | 2017-07-13 | Syddansk Universitet | Bispecific antibodies targeting human cd73 |
CN109476740A (zh) * | 2016-03-04 | 2019-03-15 | 百时美施贵宝公司 | 利用抗cd73抗体的联合治疗 |
JP7261379B2 (ja) | 2016-06-20 | 2023-04-20 | カイマブ・リミテッド | 抗pd-l1抗体 |
WO2018013611A1 (en) * | 2016-07-11 | 2018-01-18 | Corvus Pharmaceuticals, Inc. | Anti-cd73 antibodies |
MX2019006897A (es) | 2016-12-13 | 2019-08-22 | Astellas Pharma Inc | Anticuerpo anti cd73 humana. |
MY188386A (en) * | 2017-01-24 | 2021-12-07 | I Mab Biopharma Us Ltd | Anti-cd73 antibodies and uses thereof |
CA3051640A1 (en) | 2017-03-16 | 2018-09-20 | Innate Pharma | Compositions and methods for treating cancer |
WO2018187512A1 (en) * | 2017-04-04 | 2018-10-11 | Corvus Pharmaceuticals, Inc. | Methods for treating cd73hi tumors |
EP3630830A1 (en) * | 2017-05-23 | 2020-04-08 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Novel cd73 antibody, preparation and uses thereof |
EP3642240A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
WO2018237157A1 (en) * | 2017-06-22 | 2018-12-27 | Novartis Ag | CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF |
CA3074588A1 (en) * | 2017-10-06 | 2019-04-11 | Innate Pharma | Restoration of t cell activity via the cd39/cd73 axis |
SG11202002195YA (en) * | 2017-11-15 | 2020-04-29 | Innate Pharma | Potentiating the effect of atp release |
CA3083949A1 (en) | 2017-11-30 | 2020-06-06 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof |
CN117903140A (zh) | 2018-02-27 | 2024-04-19 | 因赛特公司 | 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶 |
MX2020009366A (es) | 2018-03-09 | 2020-10-14 | Phanes Therapeutics Inc | Anticuerpos anti-cd73 y usos de los mismos. |
JP7319992B2 (ja) | 2018-03-09 | 2023-08-02 | アジェナス インコーポレイテッド | 抗cd73抗体およびそれらの使用方法 |
CA3096674A1 (en) | 2018-04-12 | 2019-10-17 | Bristol-Myers Squibb Company | Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody |
CA3100731A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
EP3569618A1 (en) | 2018-05-19 | 2019-11-20 | Boehringer Ingelheim International GmbH | Antagonizing cd73 antibody |
UY38247A (es) | 2018-05-30 | 2019-12-31 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
PE20210320A1 (es) | 2018-06-01 | 2021-02-16 | Novartis Ag | Moleculas de union contra bcma y usos de las mismas |
KR20210023983A (ko) | 2018-06-18 | 2021-03-04 | 이나뜨 파르마 | 암을 치료하기 위한 조성물 및 방법 |
TWI829716B (zh) | 2018-07-05 | 2024-01-21 | 美商英塞特公司 | 作為a2a/a2b 抑制劑之稠合吡嗪衍生物 |
WO2020020307A1 (en) | 2018-07-25 | 2020-01-30 | I-Mab Biopharma Co., Ltd. | Anti-cd73 anti-pd-l1 bispecific antibodies |
CN111499747B (zh) * | 2019-01-11 | 2022-03-18 | 康诺亚生物医药科技(成都)有限公司 | 一种抗cd73单克隆抗体及其应用 |
BR112021012685A2 (pt) | 2019-01-11 | 2021-12-28 | Omeros Corp | Métodos para tratar câncer, para aumentar o nível de citocinas th1 nas células mononucleares de sangue periférico humanas, para realçar uma resposta imune antitumoral e para estimular e/ou amplificar uma resposta imune em um sujeito mamífero sofrendo de ou em risco de desenvolver câncer ou metástase de câncer, e, composição farmacêutica |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
KR20220002959A (ko) * | 2019-04-23 | 2022-01-07 | 이나뜨 파르마 에스.에이. | Cd73 차단 항체 |
AU2020289179B2 (en) * | 2019-06-06 | 2024-05-02 | Jacobio Pharmaceuticals Co., Ltd. | Binding molecule specific for CD73 and use of binding molecule |
CN112300279A (zh) * | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | 针对抗cd73抗体和变体的方法和组合物 |
JP2022547081A (ja) | 2019-09-06 | 2022-11-10 | シンフォジェン・アクシェセルスケープ | 抗cd73抗体 |
WO2021053559A1 (en) | 2019-09-18 | 2021-03-25 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
KR20220100929A (ko) | 2019-11-15 | 2022-07-18 | 젠자임 코포레이션 | 이중파라토프성 cd73 항체 |
KR20220137013A (ko) | 2020-01-03 | 2022-10-11 | 인사이트 코포레이션 | Cd73 억제제 및 a2a/a2b 아데노신 수용체 억제제 병용 요법 |
WO2021213466A1 (zh) * | 2020-04-22 | 2021-10-28 | 中山康方生物医药有限公司 | 抗cd73的抗体及其用途 |
WO2021247188A1 (en) | 2020-06-05 | 2021-12-09 | Bristol-Myers Squibb Company | Cd73 antagonist potency assay and methods of use thereof |
CN115734972A (zh) | 2020-06-22 | 2023-03-03 | 信达生物制药(苏州)有限公司 | 抗cd73抗体及其用途 |
EP4178615A1 (en) * | 2020-07-10 | 2023-05-17 | Biomolecular Holdings LLC | Tetrahedral antibodies |
CN116194483A (zh) | 2020-08-13 | 2023-05-30 | 先天制药公司 | 使用抗cd73抗体的癌症治疗方法 |
JP2023548529A (ja) | 2020-11-06 | 2023-11-17 | ノバルティス アーゲー | Cd19結合分子及びその使用 |
AU2021401052A1 (en) | 2020-12-18 | 2023-06-22 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
MX2023007850A (es) | 2020-12-29 | 2023-09-11 | Incyte Corp | Terapia combinada que comprende inhibidores de adora2a/adora2b (a2a/a2b), inhibidores de muerte programada/ligando 1 de muerte programada (pd-1/pd-l1) y anticuerpos de cumulo de diferenciacion 73 (anti-cd73). |
WO2022235569A1 (en) * | 2021-05-05 | 2022-11-10 | Corvus Pharmaceuticals, Inc. | Anti-cd73 compounds to treat oncovirus-positive cancers |
WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
WO2023206242A1 (zh) * | 2022-04-28 | 2023-11-02 | 江苏中新医药有限公司 | 无钩状效应的抗人cd73单克隆抗体 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5660827A (en) | 1992-03-05 | 1997-08-26 | Board Of Regents, The University Of Texas System | Antibodies that bind to endoglin |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
DE60334453D1 (de) | 2002-05-30 | 2010-11-18 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
JP4462964B2 (ja) * | 2003-03-10 | 2010-05-12 | 第一三共株式会社 | 癌特異的抗原を標的とした抗体 |
ES2427646T5 (es) | 2005-05-09 | 2017-08-22 | Ono Pharmaceutical Co., Ltd. | Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos |
MX2007015942A (es) | 2005-07-01 | 2008-03-07 | Medarex Inc | Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada. |
EP2078732B1 (en) | 2006-07-10 | 2015-09-16 | Fujita Health University | Method of identifying a candidate diagnostic or therapeutic antibody using flow cytometry |
US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
US20090130092A1 (en) * | 2007-10-30 | 2009-05-21 | Pinsky David J | Nucleotide phosphate dissipation as a treatment for vascular disorders |
PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
HUE034832T2 (hu) | 2008-12-09 | 2021-12-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására |
ES2646863T3 (es) | 2009-11-24 | 2017-12-18 | Medimmune Limited | Agentes de unión específica contra B7-H1 |
KR101791430B1 (ko) | 2009-11-30 | 2017-10-30 | 얀센 바이오테크 인코포레이티드 | 이펙터 기능이 제거된 항체 Fc 돌연변이체 |
AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
NZ612379A (en) | 2010-12-23 | 2014-10-31 | Janssen Biotech Inc | Active protease-resistant antibody fc mutants |
MX338353B (es) | 2011-04-20 | 2016-04-13 | Medimmune Llc | Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1. |
CN103842030B (zh) | 2011-08-01 | 2018-07-31 | 霍夫曼-拉罗奇有限公司 | 使用pd-1轴结合拮抗剂和mek抑制剂治疗癌症的方法 |
EP2844289B1 (en) | 2012-04-30 | 2019-07-17 | MedImmune, LLC | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
US9090697B2 (en) * | 2013-03-15 | 2015-07-28 | Bayer Healthcare Llc | Methods for treating bleeding disorders |
CN103278634B (zh) * | 2013-05-16 | 2015-01-07 | 中国科学院近代物理研究所 | Cd73作为肾透明细胞癌干细胞表面标志物的应用 |
CN105026428B (zh) | 2013-12-12 | 2018-01-16 | 上海恒瑞医药有限公司 | PD‑l抗体、其抗原结合片段及其医药用途 |
US20180030144A1 (en) | 2014-10-10 | 2018-02-01 | Innate Pharma | Cd73 blockade |
BR112017006464A2 (pt) | 2014-10-10 | 2018-01-30 | Innate Pharma | bloqueio de cd73 |
WO2016131950A1 (en) | 2015-02-20 | 2016-08-25 | Innate Pharma | Cd73 blockade |
WO2017016805A1 (en) | 2015-07-24 | 2017-02-02 | Innate Pharma | Methods for detecting tissue infiltrating nk cells |
WO2017064043A1 (en) | 2015-10-12 | 2017-04-20 | Innate Pharma | Cd73 blocking agents |
US20190071514A1 (en) | 2016-03-14 | 2019-03-07 | Innate Pharma | Anti-cd39 antibodies |
EP3577138A1 (en) | 2017-02-06 | 2019-12-11 | Innate Pharma | Immunomodulatory antibody drug conjugates binding to a human mica polypeptide |
KR20220002959A (ko) | 2019-04-23 | 2022-01-07 | 이나뜨 파르마 에스.에이. | Cd73 차단 항체 |
-
2015
- 2015-10-09 BR BR112017006464-2A patent/BR112017006464A2/pt active Search and Examination
- 2015-10-09 KR KR1020177011231A patent/KR102536786B1/ko active IP Right Grant
- 2015-10-09 ES ES15778310T patent/ES2821964T3/es active Active
- 2015-10-09 CA CA2957813A patent/CA2957813A1/en active Pending
- 2015-10-09 EP EP15778310.1A patent/EP3204417B1/en active Active
- 2015-10-09 CN CN201580055012.7A patent/CN106852149B/zh active Active
- 2015-10-09 MX MX2017004691A patent/MX2017004691A/es unknown
- 2015-10-09 SG SG11201701341UA patent/SG11201701341UA/en unknown
- 2015-10-09 RU RU2017105119A patent/RU2746804C2/ru active
- 2015-10-09 WO PCT/EP2015/073370 patent/WO2016055609A1/en active Application Filing
- 2015-10-09 DK DK15778310.1T patent/DK3204417T3/da active
- 2015-10-09 AU AU2015329982A patent/AU2015329982B2/en active Active
- 2015-10-09 JP JP2017518540A patent/JP7037359B2/ja active Active
- 2015-10-09 PT PT157783101T patent/PT3204417T/pt unknown
- 2015-10-09 US US15/517,991 patent/US10766966B2/en active Active
- 2015-10-09 EP EP20180074.5A patent/EP3736294A3/en active Pending
-
2017
- 2017-02-13 IL IL250579A patent/IL250579B2/en unknown
-
2020
- 2020-07-16 JP JP2020122032A patent/JP7132981B2/ja active Active
- 2020-09-02 US US17/009,817 patent/US11958907B2/en active Active
-
2021
- 2021-08-16 AU AU2021215306A patent/AU2021215306A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3204417B1 (en) | 2020-07-22 |
DK3204417T3 (da) | 2020-10-12 |
ES2821964T3 (es) | 2021-04-28 |
JP2020186244A (ja) | 2020-11-19 |
US11958907B2 (en) | 2024-04-16 |
CA2957813A1 (en) | 2016-04-14 |
IL250579A0 (en) | 2017-04-30 |
JP2018502051A (ja) | 2018-01-25 |
CN106852149A (zh) | 2017-06-13 |
RU2017105119A3 (es) | 2019-04-29 |
IL250579B1 (en) | 2023-01-01 |
RU2746804C2 (ru) | 2021-04-21 |
EP3736294A3 (en) | 2021-02-17 |
KR20170070077A (ko) | 2017-06-21 |
JP7132981B2 (ja) | 2022-09-07 |
WO2016055609A1 (en) | 2016-04-14 |
US10766966B2 (en) | 2020-09-08 |
RU2017105119A (ru) | 2018-11-12 |
EP3736294A2 (en) | 2020-11-11 |
EP3204417A1 (en) | 2017-08-16 |
KR102536786B1 (ko) | 2023-05-26 |
SG11201701341UA (en) | 2017-03-30 |
US20200392243A1 (en) | 2020-12-17 |
PT3204417T (pt) | 2020-10-08 |
AU2015329982B2 (en) | 2021-05-20 |
JP7037359B2 (ja) | 2022-03-16 |
IL250579B2 (en) | 2023-05-01 |
CN106852149B (zh) | 2021-08-27 |
AU2021215306A1 (en) | 2021-09-16 |
US20180237536A1 (en) | 2018-08-23 |
AU2015329982A1 (en) | 2017-03-09 |
BR112017006464A2 (pt) | 2018-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017004691A (es) | Bloqueo de cd73. | |
AU2018236800B2 (en) | DNA-PK inhibitors | |
PH12019500709A1 (en) | Anti-lag-3 antibodies and methods of use thereof | |
PH12017500918A1 (en) | Antibodies against cd73 and uses thereof | |
MX2023000818A (es) | Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos. | |
PH12017500915A1 (en) | Cd47 antibodies, methods, and uses | |
CA3156451A1 (en) | ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES | |
MX2018006973A (es) | Anticuerpos anti-cd73 humanizados. | |
MY195110A (en) | Antibodies to PD-1 and uses Thereof | |
EA201991214A1 (ru) | Антитела против pd-1 и их композиции | |
MX2019003489A (es) | Moleculas del receptor de envolvimiento quimerico. | |
MY192848A (en) | Compositions and methods for the treatment of hemoglobinopathies | |
EP4219689A3 (en) | Immune effector cell therapies with enhanced efficacy | |
MX2018010295A (es) | Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos. | |
MX2018002315A (es) | Anticuerpos anti muerte programada 1 (pd 1) y metodos de uso de los mismos. | |
NZ732211A (en) | Combination immunotherapy approach for treatment of cancer | |
MX2020007266A (es) | Moleculas del receptor quimerico de engullido y metodos de uso. | |
GB2532619A (en) | Sirp-Alpha Variant Constructs And Uses Thereof | |
MX2018004503A (es) | Receptores de antigeno quimerico anti-cd30. | |
MX2017007941A (es) | Anticuerpos antagonistas anti-axl. | |
MX2021014663A (es) | Il-23a y tnf-alfa orientados y compuesto y sus usos. | |
WO2015132675A3 (en) | Methods and compositions for modifying the immune response | |
MX2020003219A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. | |
MX2022002682A (es) | Anticuerpos anti-cd73. | |
MX2018008299A (es) | Metodos para administrar hepcidina. |